21 May 2013
Keywords: novartis, optaflu, cleared, eu, swiss, drug, major
Article | 18 June 2007
Swiss drug major Novartis says that Optaflu, the first influenza vaccine to utilize its proprietary cell line for the production ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 June 2007
25 June 2007
20 May 2013
© 2013 thepharmaletter.com